Novavax & Takeda Finalize Pact for Covid Vaccine Candidate

Novavax, a biotechnology company, said the company signed an exclusive license agreement for Takeda Pharmaceutical’s development, manufacturing and commercialization of NVX-CoV2373 in Japan.

• The agreement includes COVID-19 vaccine technology transfer to Takeda for local manufacturing and commercialization in Japan, according to a press release
• Takeda dosed the first participants in a Phase 2 clinical trial to test the immunogenicity and safety of Novavax’ vaccine candidate in the Japanese population
• Takeda has also begun a placebo-controlled, observer-blinded Phase 1/2 study in Japan to evaluate the immunogenicity and safety of NVX-CoV2373 (known as TAK-019 in Japan) in 200 healthy volunteers aged 20 ...